Log in

Relevant bibliographies by topics / Azilsartan

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Azilsartan'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Azilsartan.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Azilsartan"

1

Sagar, N. Katke*1 Santosh P. Kumbhar2 Vinod D. Usnale3 Siddhant M. Sawant4. "The Method Development And Validation Of A High-Performance Liquid Chromatographic Method For Azilsartan Analysis." International Journal in Pharmaceutical Sciences 2, no. 5 (2024): 1152–61. https://doi.org/10.5281/zenodo.11240815.

Full text

Abstract:

The goal of the current study is to develop an RP-HPLC-based analytical method for determining the dosage of Azilsartan in bulk and tablet form that is fast, precise, sensitive, selective, and repeatable. Create a novel HPLC technique for Azilsartan estimation, and validate it in compliance with ICH guidelines. In order to make use of the accepted methodology for Azilsartan estimation in pharmaceutical formulations, an RP-HPLC method was utilized to create and validate a stability indicating method. Using an Inertsil-ODS C18 (250×4.6mm, 5µm) column and a 90:10 v/v methanol: acetonitrile mobile phase at a flow rate of 1 ml/min, the estimation was carried out using RP-HPLC.  Azilsartan's HPLC linearity range was 20–70 µg/ml, and its R2 value was 0.999. Additionally, the method satisfies the robustness parameter requirement. The method's accuracy, precision, sensitivity, and economy are demonstrated by the findings. HPLC is a faster method. The medicinal dose form was successfully administered using the procedure.

APA, Harvard, Vancouver, ISO, and other styles

2

Lam, Sum. "Azilsartan." Cardiology in Review 19, no. 6 (2011): 300–304. http://dx.doi.org/10.1097/crd.0b013e31822e9ba3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ito, Shuichi, Yuya Nishiyama, Kenkichi Sugiura, and Kazuaki Enya. "Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study." Clinical and Experimental Nephrology 26, no. 4 (2021): 350–58. http://dx.doi.org/10.1007/s10157-021-02159-9.

Full text

Abstract:

Abstract Background Azilsartan is an angiotensin II receptor blocker indicated for the treatment of adult hypertension. A previous single-dose study suggested that azilsartan may also be a promising agent for paediatric hypertension. However, the long-term safety and efficacy of azilsartan in children have not been established. Methods We conducted a phase 3, single-arm, open-label, prospective study to evaluate the safety and efficacy of azilsartan in pediatric patients with hypertension. Twenty-seven patients aged 6–15 years were treated with once-daily azilsartan for 52 weeks. The starting dose was 2.5 mg for patients weighing < 50 kg (N = 22) and 5 mg for patients weighing ≥ 50 kg (N = 5), with doses titrated up to a maximum of 20 and 40 mg, respectively. Results Azilsartan showed acceptable tolerability at doses up to 20 mg in patients weighing < 50 kg and 40 mg in those weighing ≥ 50 kg. Most drug-related adverse events (AEs) were mild, with one patient (3.7%) experiencing a severe and serious drug-related AE (acute kidney injury). One patient (3.7%) had a mild increase in serum creatinine level, which resolved after treatment discontinuation. The blood pressure-lowering effect of azilsartan was observed as early as Week 2. Overall, approximately half of the patients achieved their target blood pressure at the end of azilsartan treatment. Conclusions Our study suggests that azilsartan has an acceptable safety profile in hypertensive patients aged 6–15 years. Azilsartan may be a promising agent for treating paediatric hypertension.

APA, Harvard, Vancouver, ISO, and other styles

4

Baker, William L., and William B. White. "Azilsartan Medoxomil for Treating Hypertension—Clinical Implications of Recent Trials." Spring 9, no. 1 (2012): 16–21. http://dx.doi.org/10.15420/usc.2012.9.1.16.

Full text

Abstract:

Objective: To evaluate the efficacy, safety, and clinical role of azilsartan medoxomil, an angiotensin-II receptor blocker (ARB) that recently gained US Food and Drug Administration approval for lowering of blood pressure (BP) in patients with hypertension. Methods: A systematic review of the literature was performed through October 2011 using the keywords and medical subject headings azilsartan, azilsartan medoxomil, TAK-491, TAK-536, and Edarbi. Citations eligible for inclusion were in vitro or in vivo evaluations of azilsartan medoxomil with no restrictions on patient population or indication used. Data related to the patient populations and outcomes of interest were extracted from each citation. Results: Three trials are available in full publication form, with others available only as abstracts. Azilsartan medoxomil 40 mg and 80 mg daily significantly improves both systolic and diastolic BP from baseline compared with placebo, and the 80 mg dose has greater efficacy than other ARBs, including olmesartan 40 mg daily and valsartan 320 mg daily. Improvements in both 24-hour BP using ambulatory monitoring and clinic BPs, as well as a higher proportion of patients reaching goal, have been seen with azilsartan medoxomil. Additional information shows added BP lowering when azilsartan medoxomil is combined with chlorthalidone. Adverse events are similar with azilsartan medoxomil compared to other ARBs and include headache, dizziness, urinary tract infections, and fatigue. Conclusions: Azilsartan medoxomil is a safe and effective ARB with a unique pharmacologic profile compared with other agents, including slowed angiotensin-II type 1 (AT1) receptor dissociation rates and improved receptor specificity. Studies have shown azilsartan medoxomil 80 mg once daily to reduce BP to a greater extent than valsartan and olmesartan, with similar safety and tolerability.

APA, Harvard, Vancouver, ISO, and other styles

5

Mahmood, Naza, and Noor Majid Raheem Kareem1. "Ameliorating Effect of Azilsartan on Cisplatin -Induced Ocular Toxicity in Male Rats." Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) 32, no. 2 (2023): 96–111. http://dx.doi.org/10.31351/vol32iss2pp96-111.

Full text

Abstract:

Objective: To evaluate the protective effect of Azilsartan against Cisplatin-induced ocular damage by ameliorating the oxidative stress and inflammation status, as well as to compare two different doses of Azilsartan to the Resveratrol. Fifty-six male Wister albino-rats, weighing 270±30 g. The rats were allocated at random into seven groups (n=8 per group), as follows: Group 1 (Healthy control) was given 0.5% CMC orally for the 14 days. Group 2 (Positive control) was given a single injection of 7mg/kg Cisplatin intraperitoneally and then 0.5% CMC orally for the following 14 days. Group 3 was given 3.5mg/kg Azilsartan orally for the following 14 days. Group 4 was given 7mg/kg Azilsartan orally for the following 14 days. Group 5 was given a single injection of 7mg/kg Cisplatin intraperitoneally and then 3.5mg/kg Azilsartan orally for the following 14 days. Group 6 was given a single injection of 7mg/kg Cisplatin intraperitoneally and then 7mg/kg Azilsartan orally for the following 14 days. Group 7 (standard) was given 25mg/kg/day Resveratrol orally for following 14 days.Azilsartan at low dose (3.5mg/kg) showed a significant reduction in IL-1β pro-inflammatory marker level, whereas there was no significant effect on MDA and SOD levels in cisplatin-induced ocular damage. Histologically, there were significant reduction in inflammatory exudates, edema, and inflammatory cells infiltration with both doses. Additionally, there were no significant difference among Azilsartan only received groups and Resveratrol group. Azilsartan shows a promising anti-inflammatory effect in ocular tissue in Cisplatin experimental rat models by significantly reducing IL-1β overexpression, through its potent AT1receptor blocking effect. However, Azilsartan showed a slight effect on MDA levels and marginal effect on SOD levels in Cisplatin-induced ocular toxicity. Furthermore, Azilsartan at a low dose slightly mimicked the effect of resveratrol on normal ocular tissue, suggesting an advancement in prophylactic application in ocular injury. Keywords: Azilsartan, IL-1β, Cisplatin, Ocular Toxicity

APA, Harvard, Vancouver, ISO, and other styles

6

Weber, Michael A., Peter Sever, Attila Juhasz, Andrew Roberts, and Charlie Cao. "A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone." Journal of the Renin-Angiotensin-Aldosterone System 19, no. 3 (2018): 147032031879500. http://dx.doi.org/10.1177/1470320318795000.

Full text

Abstract:

Introduction: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension. Methods: Azilsartan medoxomil 40 or 80 mg plus chlorthalidone were compared with placebo plus chlorthalidone once daily in a randomized, double-blind, 6-week trial. The primary endpoint was change from baseline in 24-hour mean systolic blood pressure by ambulatory blood pressure monitoring. Results: Patients ( N=551; mean age 59 years; 51.7% men) were randomly assigned to placebo plus chlorthalidone ( n=184), azilsartan medoxomil 40 mg plus chlorthalidone ( n=185), or azilsartan medoxomil 80 mg plus chlorthalidone ( n=182). Baseline systolic blood pressures were similar among groups. After 6 weeks, least squares mean (standard error) reductions with azilsartan medoxomil 40 mg and 80 mg plus chlorthalidone were similar in magnitude (−31.7 (1.0) and −31.3 (1.0) mmHg, respectively), but greater than chlorthalidone alone (−15.9 (1.0) mmHg). Hypotension and serum creatinine elevations were more frequent with azilsartan medoxomil plus chlorthalidone than chlorthalidone alone (reversed with drug discontinuation). Notably, plasma potassium reduction of 0.43 meq/L with chlorthalidone was attenuated to 0.13 and 0.05 meq/L by azilsartan medoxomil 40 mg and 80 mg, respectively. Conclusion: Azilsartan medoxomil 40 mg or 80 mg plus chlorthalidone 25 mg was significantly more efficacious than chlorthalidone alone in reducing blood pressure and was well tolerated. Clinicaltrial.gov , https://clinicaltrials.gov/ct2/show/NCT00591773 , NCT00591773

APA, Harvard, Vancouver, ISO, and other styles

7

Mohammed, Samer S., Haitham M. Kadhim, Israa M. AL-Sudani, and Wael W. Musatafa. "Anti-inflammatory Effects of Topically Applied Azilsartan in a Mouse Model of Imiquimod-induced Psoriasis." INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY 12, no. 03 (2022): 1249–55. http://dx.doi.org/10.25258/ijddt.12.3.53.

Full text

Abstract:

Background: Many studies showed a possible exacerbation of psoriasis after exposure to angiotensin receptor antagonists. Azilsartan is a competitive angiotensin II receptor antagonist and has anti-inflammatory effects in various inflammatory disorders. Objective: Investigate dose-dependent effects of topical Azilsartan on Imiquimod-induced psoriasis in mice. Methods: Forty-eight mice are allocated into six groups (8 mice per group). They all received Imiquimod for the induction of psoriasis (except Group I, a negative control group). Group II (Induction group) received petroleum gel for six days after induction with Imiquimod. The other groups (III, IV, V, and VI) were given Clobetasol propionate 0.05, 1% Azilsartan, 3% Azilsartan, and a combination of 3% Azilsartan and 0.05% Clobetasol propionate ointments, respectively once daily for six days after induction. Results: Azilsartan decreased psoriasis area severity index (PASI) score and attenuated the histological manifestations after induction. It significantly decreased the serum and tissue levels of the inflammatory biomarkers (TNF-α, IL-17, IL-23, and NF-Kβ), especially when used as an add-on therapy to Clobetasol. Conclusion: Topically-applied Azilsartan shows anti-psoriatic effects in Imiquimod-induced psoriasis in mice via anti-inflammatory and anti-proliferative activities.

APA, Harvard, Vancouver, ISO, and other styles

8

Xu, Juan, Rongkai Du, Lvying Wu, et al. "Azilsartan piperazine salt solvate and monohydrate: preparation, crystal structure, enhanced solubility and oral bioavailability." New Journal of Chemistry 44, no. 3 (2020): 852–60. http://dx.doi.org/10.1039/c9nj05042f.

Full text

Abstract:

Two azilsartan–piperazine salt solvates and a monohydrate feature crystal structural diversity and improve the azilsartan solubility over that of the free Az form. Az–Pz·EtOH and Az–Pz·H<sub>2</sub>O improve the plasma azilsartan concentration C<sub>max</sub> and AUC over the free Az form.

APA, Harvard, Vancouver, ISO, and other styles

9

Purushottam, Prajapati, and M.S. Ranawat Dr. "SIMULTANEOUS ESTIMATION OF AZILSARTAN AND CHLORTHALIDONE IN TABLET DOSAGE FORM BY VALIDATED STABILITY INDICATING RP-HPLC METHOD." International Journal of Current Pharmaceutical Review and Research 13, no. 2 (2021): 6–14. https://doi.org/10.5281/zenodo.12667239.

Full text

Abstract:

Objective: To develop and validate a simple, efficient and cost-effective stability indicatingRP-HPLC method for simultaneous estimation of Azilsartan and Chlorthalidone in Tabletdosage form. Methods: Phosphate buffer (ph4.0)-Methanol (60:40) used as mobile phase andstationary phase (250*4.6mm C18, Hypersil BDS) column, wavelength was selected 236 nm,Flow rate 1.0 ml/ min, injection volume 20 µl. Prepared Standard solution and samplesolution at working concentration, used Mobile phase as diluent. Results: Elution order ofboth peaks, Chlorthalidone (Retention time 3.470 min.) eluted first and Azilsartan (Retentiontime 5.743 min.) second with good resolution and fulfil System suitability parameters.Precision results shows % Relative standard deviation of Azilsartan and Chlorthalidone 0.8and 1.2 respectively. Linearity results of Azilsartan and Chlorthalidone found acceptable inrange 20.0 µg/ml to 120 .0 µg/ml and 12.5 µg/ml to 75.0 µg/ml, respectively. Calibrationcurve shows good linearity and Correlation coefficient was 0.9999 of Azilsartan andChlorthalidone. Recovery results of Azilsartan and Chlorthalidone from matrix of tabletformulation were 100.3% and 100.2%, respectively. Robustness and ruggedness results werefound well within the acceptance limit. Conclusion: The results shows that the proposedsimple, precise and accurate method can be successfully applied for simultaneous estimationof Azilsartan and Chlorthalidone in Tablet dosage form

APA, Harvard, Vancouver, ISO, and other styles

10

Maddi, N. V. D. Harikiran, Srinivas Garaga, Ambati V. Raghava Reddy, Paul Douglas Sanasi, and Raghubabu Korupolu. "Synthesis and characterization of related substances of Azilsartan Kamedoxomil." Current Issues in Pharmacy and Medical Sciences 30, no. 1 (2017): 31–35. http://dx.doi.org/10.1515/cipms-2017-0007.

Full text

Abstract:

Abstract Azilsartan Kamedoxomil is an AT1-subtype angiotensin II receptor blocker (ARB). During the laboratory synthesis of Azilsartan Kamedoxomil, four related substances of Azilsartan Kamedoxomil were observed and identified. These were 2-Ethoxy-3-[[4-[2- [4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-5-oxo-1,2,4-oxadiazol-3-yl]phenyl]phenyl] methyl] benzimidazole-4-carboxylic acid (azilsartan N-medoxomil, 9), (5-methyl-2-oxo- 1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-5- oxo-1,2,4-oxadiazol-3-yl]phenyl]phenyl] methyl] benzimidazole-4-carboxylate (azilsartan dimedoxomil, 10), (5-methyl-2-oxo-1,3-dioxo-4-yl)methyl 1-[2’-(4,5-dihydro-5-oxo-4H- 1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-2-methoxy-1H-benzimidazole-7-carboxylate (methoxy analogue of azilsartan medoxomil, 11), Methyl 1-((2’-amidobiphenyl-4-yl) methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (amide methyl ester, 12). The present work describes the origin, synthesis and characterization of these related substances.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Azilsartan"

1

Zhao, Mingming. "Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats." Kyoto University, 2014. http://hdl.handle.net/2433/188671.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ram, Vijay [Verfasser], Hitendra S. [Verfasser] Joshi, and Paras P. Vekariya Rajesh [Verfasser] Ram. "Development and validation of HPLC method for simultaneous quantitative determination of Azilsartan medoxomil potassium and Chlorthalidone in human plasma / Vijay Ram, Hitendra S. Joshi, Paras P. Vekariya Rajesh Ram." München : GRIN Verlag, 2014. http://d-nb.info/1184031495/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ram, Vijay [Verfasser], Hitendra S. [Verfasser] Joshi, and Paras P. Vekariya Rajesh [Verfasser] Ram. "Development and validation of HPLC method for simultaneous quantitative determination of Azilsartan medoxomil potassium and Chlorthalidone in human plasma / Vijay Ram, Hitendra S. Joshi, Paras P. Vekariya Rajesh Ram." Munich : GRIN Verlag, 2015. http://d-nb.info/1097478874/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Varela, Hugo de Almeida. "Efeitos da azilsartana sobre a doen?a periodontal em um modelo experimental com ratos wistar." Universidade Federal do Rio Grande do Norte, 2015. http://repositorio.ufrn.br/handle/123456789/19879.

Full text

Abstract:

Submitted by Automa??o e Estat?stica (sst@bczm.ufrn.br) on 2016-02-23T00:15:56Z No. of bitstreams: 1 HugoDeAlmeidaVarela_DISSERT.pdf: 3160219 bytes, checksum: 5e75a6e4f85482a68335030d7da0f1e7 (MD5)<br>Approved for entry into archive by Arlan Eloi Leite Silva (eloihistoriador@yahoo.com.br) on 2016-02-26T23:37:36Z (GMT) No. of bitstreams: 1 HugoDeAlmeidaVarela_DISSERT.pdf: 3160219 bytes, checksum: 5e75a6e4f85482a68335030d7da0f1e7 (MD5)<br>Made available in DSpace on 2016-02-26T23:37:36Z (GMT). No. of bitstreams: 1 HugoDeAlmeidaVarela_DISSERT.pdf: 3160219 bytes, checksum: 5e75a6e4f85482a68335030d7da0f1e7 (MD5) Previous issue date: 2015-03-19<br>As doen?as periodontais possuem alta preval?ncia na popula??o mundial e manifestam-se, principalmente, em duas entidades distintas, a saber: a gengivite induzida pela placa bacteriana e a periodontite. A periodontite ? uma doen?a inflamat?ria cr?nica caracterizada pela destrui??o em v?rios n?veis do osso alveolar, fibras col?genas e do cemento, ? considerada importante causa de perda dent?ria em adultos. Estudos experimentais recentes demonstram o efeito anti-inflamat?rio e antirreabsortivo dos f?rmacos anti-hipertensivos da classe dos bloqueadores dos receptores de angiotensina II sobre a doen?a periodontal. O objetivo desse estudo foi avaliar os efeitos da azilsartana (AZT) um potente inibidor dos receptores de angiotensina II que apresenta efeitos adversos m?nimos, sobre a perda ?ssea alveolar, inflama??o, express?o das metaloproteinases da matriz (MMP), ligante do receptor do fator nuclear kapa B (RANKL), receptor ativador do fator nuclear kapa B (RANK), osteoprotegerina (OPG), ciclooxigenase-2 (COX-2), Interleucina 10, Interleucina 1?, TNF-?, glutationa (GSH) e catepsina K no modelo de doen?a periodontal induzida por ligadura em ratos. Foram utilizados 100 ratos wistar sendo divididos randomicamente em 5 grupos com 20 ratos cada: (1) n?o foi induzida a doen?a periodontal, ?gua destilada, (2) indu??o da doen?a periodontal, ?gua destilada; (3) indu??o da doen?a periodontal, AZT 1 mg/kg; (4) indu??o da doen?a periodontal, AZT 5 mg/kg; e (5) indu??o da doen?a periodontal, AZT 10 mg/kg. Todos os grupos foram tratados com ?gua destilada ou AZT por 10 dias. Os tecidos periodontais foram submetidos ?s an?lises morfom?trica, histopatol?gica e imunohistoqu?mica para detec??o de MMP-2, MMP-9, RANKL, RANK, OPG e catepsina K. N?veis de IL-1?, IL-10, TNF-? foram determinados por ELISA e n?veis de mieloperoxidase(MPO) e glutationa(GSH) por espectrofotoscopia de UV vis?vel. O tratamento com AZT 5 mg/kg reduziu o MPO (p <0.05) e IL-1? (p <0.05), elevou os n?veis de IL-10 (p <0.05), reduziu a express?o de MMP-2, MMP-9, RANK, RANKL, catepsina K, e elevou a express?o de OPG. Os achados revelam que a AZT na dosagem 5mg/kg apresenta a??o anti-inflamat?ria na doen?a periodontal induzida por ligadura reduzindo a perda ?ssea alveolar, diminuindo os n?veis de citocinas pr?-inflamat?rias e elevando a express?o de agentes anti-inflamat?rios.<br>Periodontal diseases, highly prevalent disease in worldwide population, manifest primarily in two distinct entities: plaque-induced gingivitis and periodontitis. Periodontitis is a chronic inflammatory disease characterized of different levels of collagen, cementum, and alveolar bone destruction. Recent experimental studies demonstrated anti-inflammatory and antirreabsortive effect of antihypertensive agents of the angiotensin II receptor blockers class on periodontal disease. The aim of this study was to evaluate the effects of azilsartan (AZT), a potent inhibitor of the angiotensin II receptor which has minimal adverse effects on bone loss, inflammation, and the expression of matrix metallo proteinases (MMPs), receptor activator of nuclear factor kB ligand (RANKL), receptor activator of nuclear factor kB (RANK), osteoprotegerin (OPG), cyclooxygenase-2 (COX-2), and cathepsin K in periodontal tissue in a rat model of ligature-induced periodontitis. Male Wistar albino rats were randomly divided into 5 groups of 20 rats each: (1) nonligated, water; (2) ligated, water; (3) ligated, 1 mg/kg AZT; (4) ligated, 5 mg/kg AZT; and (5) ligated, 10 mg/kg AZT. All groups were treated with water or AZT for 10 days. Periodontal tissues were analyzed by morphometric exam, histopathology and immunohistochemical detection of MMP-2, MMP-9, COX-2, RANKL, RANK, OPG, and cathepsin K. Levels of IL-1b, IL-10, TNF-a, myeloperoxidase (MPO), and glutathione (GSH) were determined by ELISA. Treatment with 5 mg/kg AZT resulted in reduced MPO (p?0.05) and IL-1b (p?0.05) levels and increased in Il-10 levels (p?0.05). It was observed a reduced expression of MMP-2, MMP-9, COX-2, RANK, RANKL, cathepsin K, and a increased expression of OPG in the animals subjected to experimental periodontitis and threated with AZT (5 mg/kg). Conclusions: These findings suggest an anti-inflammatory and anti-reabsortive effects of AZT on ligature-induced periodontitis in rats.

APA, Harvard, Vancouver, ISO, and other styles

5

Chiu, Hsiao-Ping, and 邱筱萍. "Physician’s acceptance for new drugs : Azilsartan Case." Thesis, 2017. http://ndltd.ncl.edu.tw/handle/58hke4.

Full text

Abstract:

碩士<br>義守大學<br>管理碩博士班<br>105<br>The pharmaceutical industry in Taiwan has been covered by the government’s national health insurance for the past 21 years.While the aging population in Taiwan has been increasing the funds in the national health insurance have been decreasing.Under the burden of a limited increase in health premium income the budgeting system has done away with supporting patented medication and opened up the opportunity to subsidies the introduction and use of low cost generic medication.The governments of the U.S.A. and Taiwan are rigorous in approving new drugs. Which severely impacts the competitiveness of pharmaceutical companies in their ability to make a profit as they compete with each other to market their products. Therefore the patented pharmaceutical industry enters the era of low growth but highly competitive market of drug sales. All the while competing with low cost generic drugs. New drugs from major pharmaceutical companies that invest large amounts of resources into research and development and are listed on stock exchanges that have shareholders have to come up with new and innovative methods to market their products to keep the company viable as they invest in more innovative medicines. The competitive nature of how to formulate a system and business strategy to allow your drugs to enter the market becomes of the utmost importance for the survival of the pharmaceutical company.At the same time as ensuring a high level of integrity and professionalism in the industry in the marketing of prescription drugs.Thus there is this important system of how to differentiate the benefits of your product compared to the benefits of others and thereby increase its competiveness in the medical field. Therefore the marketing of the drug becomes ever important to gain its attention.In a study conducted in the southern district hospitals to find out the consumer habits between the patients and physicians regarding prescription medication and to explore the theory of planned behavior technology, a survey was comprehensively carried out to verify the behavioral patterns between physician and patient. The survey was conducted at numerous hospitals and involved a number of physicians to verify its findings regarding prescription medicines.The total number of questionnaire samples sent out was 120, with a return of 116 answered in detail. The information was informative and well written out in regards to the theory of planned behavior attitudes (TPA), subjective norms and technology acceptance mode (TAM).Therefore the onus of prescribing medication falls on the physician and his positive or negative views of the drug, determining which medication they will prescribe. Taking into consideration their patients needs and the community to which they serve, Confidence grows in the physician to prescribe medication that has yielded positive results.

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Azilsartan"

1

Blokdijk, G. J. Azilsartan Kamedoxomil; The Ultimate Step-By-Step Guide. CreateSpace Independent Publishing Platform, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Joshi, Hitendra S., and Paras P. Vekariya Rajesh Ram. Development and Validation of HPLC Method for Simultaneous Quantitative Determination of Azilsartan Medoxomil Potassium and Chlorthalidone in Human Plasma. GRIN Verlag GmbH, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Azilsartan"

1

"Azilsartan." In PharmacotherapyFirst Drug Information. The American Pharmacists Association, 2017. http://dx.doi.org/10.21019/druginformation.azilsartan.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Al-Majed, Abdulrahman A., Ahmed H. H. Bakheit, Ali Al-Muhsin, Hamad M. Al-Kahtani, and Ali S. Abdelhameed. "Azilsartan medoxomil." In Profiles of Drug Substances, Excipients and Related Methodology. Elsevier, 2020. http://dx.doi.org/10.1016/bs.podrm.2019.10.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Wardhan, Harsh, and Nitin Aggarwal. "Azilsartan for Hypertension Management in Cardiodiabetes." In Cardiodiabetes Update: A Textbook of Cardiology. Jaypee Brothers Medical Publishers (P) Ltd., 2018. http://dx.doi.org/10.5005/jp/books/14130_95.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Daga, Lal, and Suman Bhandari. "Azilsartan: Promise and Power for Hypertension in Cardiodiabetes." In Cardiodiabetes Update: A Textbook of Cardiology. Jaypee Brothers Medical Publishers (P) Ltd., 2018. http://dx.doi.org/10.5005/jp/books/14130_74.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chopra, HK, AK Pancholia, and Viveka Kumar. "Azilsartan: A Molecule of First Choice for Hypertension in Cardiodiabetes." In Cardiodiabetes Update: A Textbook of Cardiology. Jaypee Brothers Medical Publishers (P) Ltd., 2018. http://dx.doi.org/10.5005/jp/books/14130_76.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Azilsartan"

1

Shrestha, A. B., H. Singh, R. S. Yadav, et al. "Efficacy and Safety of Combinations of Azilsartan- Medoximil/Chlorthalidone Versus Olmesartan-medoximil/Hydrochlorothiazide Among Hypertensive Patients: A Meta- Analysis." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5732.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!